|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 44, 128-135, January 2003
Copyright © 2003 by Lipid Research, Inc.
Eisai Co. Ltd., Tsukuba Research Laboratories, Ibaraki, Japan
1 To whom correspondence should be addressed. e-mail: h-hiyoshi{at}hhc.eisai.co.jp
We recently demonstrated that squalene synthase (SQS) inhibitors reduce plasma triglyceride through an LDL receptor-independent mechanism in Watanabe heritable hyperlipidemic rabbits (Hiyoshi et al. 2001. Eur. J. Pharmacol. 431: 345352). The present study deals with the mechanism of the inhibition of triglyceride biosynthesis by the SQS inhibitors ER-27856 and RPR-107393 in rat primary cultured hepatocytes. Atorvastatin, an HMG-CoA reductase inhibitor, had no effect on triglyceride biosynthesis, but reversed the inhibitory effect of the SQS inhibitors. A squalene epoxidase inhibitor, NB-598, affected neither triglyceride biosynthesis nor its inhibition by ER-27856 and RPR-107393. The reduction of triglyceride biosynthesis by ER-27856 and RPR-107393 was potentiated by mevalonolactone supplementation. Treatment of hepatocytes with farnesol and its derivatives reduced triglyceride biosynthesis. In addition, we found that ER-27856 and RPR-107393 significantly reduced the incorporation of [1-14C]acetic acid into oleic acid, but not the incorporation of [1-14C]oleic acid into triglyceride. Though ER-27856 and RPR-107393 increased mitochondrial fatty acid ß-oxidation, the inhibition of ß-oxidation by RS-etomoxir had little effect on their inhibition of triglyceride biosynthesis.
These results suggest that SQS inhibitors reduce triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives.
Abbreviations: CHD, coronary heart disease; CPT I, carnitine palmitoyltransferase I; SQS, squalene synthase; FPP, farnesyl pyrophosphate; MVL, mevalonolactone; SD rats, Sprague-Dawley rats; WHHL rabbit, Watanabe heritable hyperlipidemic rabbit
Supplementary key words ER-27856 RPR-107393 HMG-CoA reductase squalene epoxidase isoprenoid pathway
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. C. Fernandes Rodrigues, J. L. Concepcion, C. Rodrigues, A. Caldera, J. A. Urbina, and W. de Souza In Vitro Activities of ER-119884 and E5700, Two Potent Squalene Synthase Inhibitors, against Leishmania amazonensis: Antiproliferative, Biochemical, and Ultrastructural Effects Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4098 - 4114. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Okazaki, F. Tazoe, S. Okazaki, N. Isoo, K. Tsukamoto, M. Sekiya, N. Yahagi, Y. Iizuka, K. Ohashi, T. Kitamine, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver J. Lipid Res., September 1, 2006; 47(9): 1950 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Murthy, H. Tong, and R. J. Hohl Regulation of Fatty Acid Synthesis by Farnesyl Pyrophosphate J. Biol. Chem., December 23, 2005; 280(51): 41793 - 41804. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |